Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Sep 05, 2018 2:23pm
171 Views
Post# 28567008

RE:RE:RE:ANTIBE LONGs rewarded for patience!

RE:RE:RE:ANTIBE LONGs rewarded for patience!Hey SergeantSanderz,

Don't get me wrong, I'm with you, I expect good things from ATE. I'm long and been invested for years. I only took out enough money to cover my initial investment when it popped. I was lucky my average cost was 0.14 I only had to sell about 25% of my large position. So I still have a large position and great expectations for Antibe.
That being said, the last time I looked into Phase 3 trials, I've seen numbers go even higher, up in the 50-60 Millions for costs. I don't think ours will cost that much. Dan has said we have to do 2 Phase 3 trials. Our phase 2 trials costs between 2.5-5 million. We know Phase 3 will be an order of magnitude more as they are historically. As I said, I was guessing on the numbers. 

I still don't feel they will have enough to do the 2 full Phase 3 trials, especially with Citagenix bleeding them dry.

But you are correct, there are avenues that could get them there. Pending the milestone payments (which I would guess most are on the tail end rather then the front end as you suggest). Also pending other smaller reginonal deals and the big unknown if Citagenix can become cashflow positive and start generating revenue are all things that can play into it.

So yes it's possible the stars align and they have the funds to commence phase 3 and maybe even get through most of it. 

Bottom line, the startigic direction management is pushing is to sell or partner prior to Phase 3, I'm still going for that.
Bullboard Posts